Abstract: The present invention resides in a method for the manufacture of a disulphide-requiring biopharmaceutical having an element of at least tertiary structure using wild type E. coli.

Abstract: The present invention resides in a method for the manufacture of a disulphide-requiring biopharmaceutical having an element of at least tertiary structure using wild type E. coli.

Abstract: The present invention relates to a photosensitive composition comprising synthetic nanocrystalline hydroxyapatite or a synthetic precursor thereof doped with a rare earth ion, the use of the composition in restorative or cosmetic dentistry, a process for preparing the composition and a method of generating an image of an exposed dentinal surface of a tooth.

Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.

Abstract: The present invention relates to a photosensitive composition comprising synthetic nanocrystalline hydroxyapatite or a synthetic precursor thereof doped with a rare earth ion, the use of the composition in restorative or cosmetic dentistry, a process for preparing the composition and a method of generating an image of an exposed dentinal surface of a tooth.

Abstract: The present invention relates, inter alia, to the crystal structures of a phosphodiesterase 5 (PDE5) and PDE5/PDE5 ligand complex and their uses in identifying PDE5 ligands, including PDE5 inhibitor compounds. The present invention also relates to methods of identifying such PDE5 inhibitor compounds and their medical use. Also contemplated by the present invention are crystals of PDE5/PDE5 inhibitor complexes.

Abstract: The present invention relates to the soakable crystals of a phosphodiesterase 5 (PDE5) and their uses in identifying PDE5 ligands, including PDE5 ligands and inhibitor compounds. The present invention also relates to methods of identifying such PDE5 inhibitor compounds and their medical use. The present invention additionally relates to crystals of PDE5 into which ligands may be soaked and crystals of PDE5 comprising PDE5 ligands that have been soaked into the crystal.

Abstract: The invention relates to the crystalline formic acid solvate of (6R, 7R)-7-[(Z)-2-(2-Aminothiazol-4-y1)-2-(2-carboxyprop-2-oxyimino)acetamido]- 3-(1-pyridiniummethyl)ceph-3-em-4-carboxylate dihydrochloride (ceftazidime dihydrochloride).The crystalline solvate is a useful intermediate in the preparation of forms of ceftazidime suitable for administration, e.g. the pentahydrate.

Abstract: A process for the separation of a mixture of syn and anti oxime isomers one from the other which comprises adsorbing said mixed oxime isomers onto a non-functional macroreticular adsorption resin, and eluting said resin to yield at least one eluate fraction containing one of said isomers while being substantially free of the other of said isomers.The application of this process to the separation of syn and anti isomers of cephalosporin compounds possessing an oxime grouping in a side-chain in the 7.beta.-position, and of acids corresponding to this 7.beta.-side chain, is described.

Abstract: A process for recovering ceftazidime from an aqueous solution containing it, said solution being at a pH in the range 2.0 to 5.5, which comprises contacting the said solution with a non-functional macroreticular resin suitable for adsorbing ceftazidime, eluting the ceftazidime and isolating it, if desired in the form of a salt or hydrate.

Abstract: A process for the separation of a mixture of syn and anti oxime isomers one from the other which comprises adsorbing said mixed oxime isomers onto a non-functional macroreticular adsorption resin, and eluting said resin to yield at least one eluate fraction containing one of said isomers while being substantially free of the other of said isomers.The application of this process to the separation of syn and anti isomers of cephalosporin compounds possessing an oxime grouping in a side-chain in the 7.beta.-position, and of acids corresponding to this 7.beta.-side chain, is described.

Abstract: N-blocked amino acids, particularly derived from natural sources such as fermentation liquors, are extractively esterified from aqueous media by treatment of the aqueous solution with a diazoalkane, e.g. diphenyldiazomethane, in the presence of a water-immiscible organic solvent. Useful applications of the process include the extractive esterification of N-blocked derivatives of cephalosporin C and desacetyl cephalosporin C from fermentation broths.